133208-93-2

Basic information

• Product Name: NO-1886
• Synonyms: NO-1886;4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide;ibrolipim;Diethyl 4-[(4-bromo-2-cyanophenyl)carbamoyl]benzylphosphonate, Ibrolipim, OPF 009;Diethyl 4-[(4-bromo-2-cyanophenyl)carbamoyl]benzylphosphonate;OPF 009;Lipoprotein Lipase Activator;N-(4-bromo-2-cyanophenyl)-4-(diethoxyphosphorylmethyl)benzamide
• CAS NO: 133208-93-2
• Molecular Formula: C₁₉H₂₀BrN₂O₄P
• Molecular Weight: 451.25
• Mol File: 133208-93-2.mol
• Article Data: 6

Chemical Properties

• Melting Point: 160.5-162.1 °C
• Boiling Point: 512.5°C at 760 mmHg
• Flash Point: 263.7°C
• Appearance: off-white to pale yellow/
• Density: 1.44g/cm³
• Vapor Pressure: 1.29E-10mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: 2-8°C
• Solubility: DMSO: ≥20mg/mL
• CAS DataBase Reference: NO-1886(CAS DataBase Reference)
• NIST Chemistry Reference: NO-1886(133208-93-2)
• EPA Substance Registry System: NO-1886(133208-93-2)

Safety Data

• Hazard Codes: Xi,T
• Statements: 36/37/38-25
• Safety Statements: 26-36-45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 133208-93-2(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 133208-93-2 differently. You can refer to the following data:
1. Antiatherogenic; antiobesity; antidyslipidemia; anticachexia; and antidiabetes/syndrome.
2. Lipoprotein Lipase Activator is an inducer of lipoprotein lipase mRNA.

InChI:InChI=1/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23)

Upstream product

• 39263-32-6 2-amino-5-bromobenzonitrile 
• 118578-91-9 4-[(diethoxyphosphoryl)-methyl]benzoyl chloride 
• 1122-58-3 dmap 
• 28149-48-6 4-[(diethoxyphosphinyl)methyl]benzoic acid 

Downstream Products

• 166394-32-7 [4-(6-Bromo-4-hydroxy-quinazolin-2-yl)-benzyl]-phosphonic acid diethyl ester 

Relevant articles and documents

Agent for preventing and curing fatty liver and method for curing thereof

The present invention provides an agent for preventing and curing fatty liver containing, as the effective ingredient compound, a carboxylic acid amide derivative represented by the general formula (1), (wherein R is a lower alkyl group; and X is a halogen atom), and a method for curing fatty liver by administering said agent.

Phosphonic diester derivatives

The present invention provides a phosphonic diester derivative of the following general formula (1): STR1 wherein A represents an oxygen atom or a sulfur atom; R1, R2, R9 and R10 are the same or different and th

Method for treating hyperlipidemia

A pharmaceutical composition for treating hyperlipidemia containing, as the active ingredient, at least one carboxamide compounds represented by the formula (1) which possess excellent activities in lowering serum lipid, as well as having low toxicity with high safety. Said carboxamide compounds represented by the formula (1) are known compounds developed by the present inventors, but the pharmacological activities for treating hyperlipidemia have not been found yet.